ストックスクリーナーアプリを入手
12.83
0.83%
-0.0962
Eyepoint Inc (EYPT) 最新ニュース
(EYPT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
How The EyePoint (EYPT) Narrative Is Evolving With DURAVYU Trials And New Analyst Targets - Yahoo Finance
EyePoint Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
EyePoint Announces Participation at Upcoming Investor Conferences - The Manila Times
EyePoint lines up Goldman Sachs, Jefferies, Stifel fireside chats - Stock Titan
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Sahm
Should I Buy EYPT (EyePoint Pharmaceuticals, Inc.) | AI Analysis, Technical & News Insights - Kavout
EyePoint, Inc. Grants Stock Options to New Employees as Inducement Awards | EYPT Stock News - Quiver Quantitative
Assessing EyePoint (EYPT) Valuation After Recent Share Price Weakness - Yahoo Finance
[SCHEDULE 13G/A] EyePoint, Inc. Amended Passive Investment Disclosure - Stock Titan
EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data - Sahm
EyePoint’s DURAVYU Receives Third Consecutive Positive DSMC Review for Wet AMD - The Clinical Trial Vanguard
EyePoint Pharmaceuticals Says Phase 3 Eye Drug Trials Clear Safety Review - Moomoo
EyePoint (EYPT) Receives Positive Review for Duravyu Trials - GuruFocus
EyePoint Pharmaceuticals stock (US30233B1098): Phase 3 trials clear third safety review - AD HOC NEWS
EyePoint Announces Third Positive DSMC Review for DURAVYU Phase 3 Wet AMD Trials, Topline Data Expected Mid-2026 - Minichart
EyePoint's late-stage eye drug trials to continue after safety panel review - TradingView
EyePoint’s wet AMD trial continues after safety review By Investing.com - Investing.com Australia
Eyepoint announces third consecutive positive DSMC recommendation for phase 3 wet AMD trials for Duravyu(TM), building confidence ahead of mid-2026 topline data - marketscreener.com
EyePoint Advances DURAVYU Phase 3 Wet AMD Program - TipRanks
EyePoint’s wet AMD trial continues after safety review - Investing.com India
EyePoint receives third positive DSMC review; Phase 3 topline data on track for mid-2026 - TradingView
Third positive DSMC review backs EyePoint (EYPT) Phase 3 DURAVYU wet AMD trials - Stock Titan
Eyepoint Inc Announces Third Consecutive Positive Dsmc Recommendation for Phase 3 Wet Amd Trials for Duravyu - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
EyePoint: DURAVYU's Durability Could Drive Significant Upside (NASDAQ:EYPT) - Seeking Alpha
Adage Capital files amendment: 3,300,000 shares in EyePoint (EYPT) disclosed - Stock Titan
TradingKey - TradingKey
Liquidity Mapping Around (EYPT) Price Events - Stock Traders Daily
EyePoint Pharmaceuticals stock (US30233B1098): Trading at discount to fair value estimates - AD HOC NEWS
Mizuho Securities Reaffirms Their Buy Rating on EyePoint Pharmaceuticals (EYPT) - The Globe and Mail
Is It Too Late To Consider EyePoint (EYPT) After A 133% One-Year Surge? - simplywall.st
HC Wainwright Issues Pessimistic Forecast for EYPT Earnings - MarketBeat
Is EyePoint’s Revenue Slide and DURAVYU Cash Runway Altering The Investment Case For EyePoint (EYPT)? - simplywall.st
H.C. Wainwright Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $30 - Moomoo
EyePoint, Inc. (EYPT) Stock Analysis: A Biotech Gem With 177% Potential Upside - DirectorsTalk Interviews
EyePoint Announces First Quarter 2026 Revenue Results - VisionMonday.com
EyePoint (EYPT) Reports Strong Q1 Revenue and Anticipates Key Tr - GuruFocus
RBC Capital Maintains EyePoint(EYPT.US) With Buy Rating, Cuts Target Price to $37 - Moomoo
EYPT Maintains Rating by RBC Capital -- Price Target Lowered to $37 - GuruFocus
EyePoint 1Q Loss $84.8M >EYPT - Moomoo
[10-Q] EyePoint, Inc. Quarterly Earnings Report - Stock Titan
EyePoint (EYPT) Q1 2026 Earnings Transcript - AOL.com
MSN Money - MSN
Guggenheim reiterates Buy on EyePoint stock, cites trial progress By Investing.com - Investing.com India
RBC Capital Adjusts EyePoint Pharmaceuticals PT to $37 From $39, Maintains Outperform Speculative-Risk Rating - marketscreener.com
A Quick Look at Today's Ratings for EyePoint(EYPT.US), With a Forecast Between $20 to $43 - Moomoo
EyePoint Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Number of shareholders of EyePoint, Inc. – LSX:A2QJRU - TradingView
Guggenheim reiterates Buy on EyePoint stock, cites trial progress - Investing.com UK
2.25%
0.46%
大文字化:
|
ボリューム (24 時間):